Last edition
News about "Ichnos Sciences signs licensing pact with Almirall"
Glenmark's subsidiary, Ichnos Sciences signs licensing pact with Almirall
Glenmark's 100% subsidiary Ichnos Sciences Inc., a global biotechnology company developing innovative biologics in oncology and autoimmune diseases, and Almirall S.A, a global biopharmaceutical company focused on skin health, announced today that they have entered into an exclusive licensing agreement for the IL-1RAP antagonist ISB 880
Ichnos Sciences Signs Licensing Pact With Almirall | 14/12/2021 | By Darshana | 766
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy